Dr. Peter Bornstein MD
Epidemiologist , HEALTHEAST CARE SYSTEM
Member of the Healthcare Council
Council Member Biography
Peter Bornstein, MD, is Managing Partner and Consultant in Infectious Diseases at St. Paul Infectious Disease Associates, in St. Paul, Minnesota. Dr. Bornstein is the Chief of Staff at St. John's Hospital, Maplewood, MN. He is also Epidemiologist at HealthEast Care Systems, a four hospital consortium, responsible for oversight of infection control activities. He spends most of his time seeing critically ill and chronically ill patients. He is a past Chairman of the Antibiotic Subcommittee of the Pharmacy and Therapeutic Committee at HealthEast. Dr. Bornstein formerly served a voluntary position as the Medical Director of Amigos de las Americas, an international non-profit public health and community development agency. Since 1997, he has been named a "Top Doc" in Infectious Diseases in a poll of physicians and nurses for Minneapolis-St. Paul Magazine. Dr. Bornstein is pursuing an MBA at the Carlson School of Management of the University of Minnesota. (This is me - Update Profile)
Employment History
- 2011 - Unspecified
- Epidemiologist , HEALTHEAST CARE SYSTEM
- 2009 - Unspecified
- Chief of Staff, St. John's Hospital
- 1999 - Unspecified
- Chairman of Infection Control, HEALTHEAST CARE SYSTEM
- 1993 - Unspecified
- Partner and Consultant in Infectious Diseases, ST. PAUL INFECTIOUS DISEASE ASSOCIATES, LTD.
- 1991 - 1993
- Fellow, Infectious Diseases, Northwestern University Medical School
- 1987 - 1991
- Resident Physician, Henry Ford Hospital
GLG NewsSM Analyses by Peter Bornstein
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Documenting What We Knew All Along
July 13, 2011
A Little Placebo Effect For the Common Cold | online.wsj.com
This article from the Wall Street Journal discusses a randomized, double-blind placebo controlled trial on the effectiveness of echinacea and placebo for the common cold. Unsurprisingly, it demonstrated that taking a pill--any pill, including a placebo--reduces symptom severity and duration, compared to "doing nothing."
-
May 28, 2010
For physicians to exodus from government programs, they must have someplace to go to. The practice style and location of physicians will dictate whether they stay or leave government programs. Some physicians will find they cannot leave government programs, so will either have to accept lower payment; close, sell or merge their practice; or leave medical practice altogether.
-
The good news is that these drugs are already approved
October 28, 2009
Triple-combo Drug Shows Promise Against Antiviral Resistant H1N1 | www.medicalnewstoday.com
Adamas has a proprietary mixture of three drugs: amantadine, oseltamivir and ribavirin to treat antiviral resistant strains of novel H1N1 Influenza A.
-
Potential game changer for patients and hospitals regarding C. difficile colitis
July 18, 2009
Rapid DNA Test to Detect Clostridium difficile Infection Approved by FDA Today | www.medscape.com
Clostridium difficile-associated colitis is a disabling, and potentially life-threatening infection. Moreover, hospitals spend great resources in isolating patients with this disease to prevent infection within the hospital. This new technology from Cepheid offers faster, and more accurate diagnosis, leading to potentially quicker treatment for patients, but potentially huge savings for hospitals, that can shorten isolation periods for these patients.
-
18 months too late for this outbreak, but may be the way toward the future.
July 8, 2009
Cadila Pharma-Novavax JV to produce swine flu vaccine | www.business-standard.com
The referenced article states that the joint venture would begin producing swine flu vaccine in two years, possibly based on viral-like particle (VLP) technology. While this is too late to have significant impact in the current pandemic, it points to possible future technologies for vaccine development.
GLG Study Groups with Peter Bornstein(?)
| Study Group Name | No. Members |
|---|---|
| Infectious Diseases Physicians (US) | 867 |
| Cubicin Prescribers (US) | 220 |
| Physicians who Treat HCV (US) | 195 |
| Physicians who Treat Sepsis (US) | 134 |
GLG Live Meetings with Peter Bornstein(?)
Peter Bornstein has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.